TG Therapeutics Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib

TG Therapeutics (NASDAQ:TGTX) announced the publication of the results from the Phase 1 first-in-human study of umbralisib (TGR-1202), the Company’s novel once-daily PI3K delta inhibitor, in The Lancet Oncology.

As quoted in the press release:

These data, in addition to the unique structural attributes and enhanced selectivity profile of umbralisib, are described further in the manuscript entitled, “Umbralisib, a novel PI3K and casein kinase-1 epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study,” which was published yesterday in The Lancet Oncology.

Click here to read the full press release.